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Abstract 
Chronic viral infections, such as HIV and HCV, are common throughout the developed and 
developing world and cause devastating illness. There is a need to better understand how to 
engage the adaptive immune system to control or limit infection to reduce the negative health 
consequences of infection. Natural killer (NK) cells contribute to immune defense against many 
virus infections by recognizing and killing infected cells. However, we have identified an 
inhibitory role for NK cells in relation to antiviral T cell activity during lymphocytic 
choriomeningitis virus (LCMV) infection in mice. The underlying mechanism(s) by which NK 
cells limit virus-specific T cell responses is unclear, but two hypothesis have been proposed: 
either NK cells recognize and kill activated T cells, a process countered by interferon signaling 
into T cells, or NK cells impair the induction of T cell responses. We have previously shown that 
type-2 interferon (IFNg), like type-1 interferon, acts directly on T cells to promote antiviral T cell 
responses to acute LCMV infection. Here, we examined whether IFNg acts directly on T cells to 
protect them from the inhibitory effects of NK cells. We compared the accumulation of virus-
specific IFNgR+/+ and IFNgR-/- T cells in the same infected mice, expecting that IFNgR-/- T 
cells would be removed by NK cells. We observed that NK cell depletion increased the number 
of both cell populations and there was no preferential rescue of IFNgR-/- T cells, suggesting that 
IFNgR signaling to T cells does not protect them from NK cell suppression. We also considered 
whether NK cells inhibit antigen presentation by Antigen Presenting Cells (APCs) to curtail the 
induction of T cell responses. We measured the ability of APCs from infected mice to process 
soluble antigen utilizing fluorescent DQ-OVA and flow cytometry. Our data suggest that NK cell 
depletion improves APC processing of DQ-OVA, especially in monocyte populations. These 
data suggest that NK depletion allows for better stimulation of T cells by APCs, leading to 
greater outgrowth of T cells during infection. Thus, NK cells limit the induction of antiviral T cells, 
a process that may be conserved for T cell responses to chronic human virus infections.  
 
Introduction 
The immune system consists of organs and cells that work to protect the body from 
harmful bacteria and viruses. Infected cells produce type-I interferons, which act to restrict virus 
replication, and stimulate cells of the innate and adaptive immune systems. Innate responses 
include the induction of inflammatory cytokines, and the activation of natural killer cell (NK) 
cytotoxicity, antigen presenting cell (APC) expression of immune stimulatory molecules, and 
subsets of leukocytes. The adaptive immune system, which includes T cells and B cells, is 
triggered by the innate system and is characterized by pathogen specificity. T and B cell 
responses are triggered in response to antigen and signaling molecules such as interferons 
(IFN). T cells are activated through the recognition of antigen peptides presented by APCs 
(Cook et al., 2012). APCs such as macrophages, dendritic cells (DCs), and B-cells endocytose 
antigen in the extracellular fluid, process it, and present it as small peptides using surface MHC 
I and MHC II molecules to stimulate T cells (Young et al., 2007; Cook et al., 2012). 
NK cells are activated by interferons (IFN) and by certain host or viral ligands that are 
present on the cell-surface. During viral infection NK cells produce IFNg and other cytokines 
and can exert direct cytotoxic activity against cells infected by the pathogen through the use of 
perforin and granzyme. In addition to the well-established role of NK cells in limiting viral 
infection, NK cells can modulate adaptive immune responses. NK cells can promote immune 
cell activity through their expression of pro-inflammatory cytokines (eg, IFNg, and TNFa), or NK 
cells can inhibit immune responses through mechanisms that are still being resolved. 
NK cells and T cells are responsive to interferons during infection. Three types of 
interferons that are induced during infection: type-1 (IFNa and IFNb), type-2 (IFNg), and type-3 
(IFN-lambda). Type-I IFN is produced by infected cells and acts directly on CD8+ T cells to aid 
their expansion and function during viral infections (Koluman et al., 2005). The main sources of 
IFNg are effector T cells and NK cells. IFNg aids in T cell differentiation and viral clearance 
during chronic infection (Mack et al., 2015; Ge et al 2012; Louten et al., 2006). Like type-1 IFN, 
IFNg acts in a direct manner on CD8+ T cells to greatly increase T cell accumulation and further 
differentiation into the memory T cell subset during viral infection with LCMV (Koluman et al., 
2005; Whitmire et al., 2005).  
To better understand the relationship between interferons, NK cells, and T cell defense, 
we have used to the LCMV infection in a mouse model. LCMV is a single-stranded RNA 
arenavirus which naturally replicates in mice. The Armstrong strain causes an acute infection, 
and the Clone-13 strain disseminates to cause a chronic infection. Control of both strains 
depends upon T cell responses. However, T cells can lose antiviral activity allowing for viral 
persistence during Clone-13 infection. T cells in LCMV-Cl13 infected mice show reduced 
effector function, expression of inhibitory receptors, and overall T cell dysfunction (Wherry, 
2011). It has been shown that CD8+ T cell responses are improved during LCMV infection upon 
NK cell depletion (Cook et al., 2012). This results in a more robust immune response due to 
increased number and function of T cells, resulting in a decreased viral load. However, this 
increased immune response can often be too robust, resulting in immunopathology against the 
host. Thus, NK cells may serve a regulatory role to limit T cell mediated pathogenesis during 
infection. 
The process by which NK cells limit immune defenses is currently being investigated and 
differing mechanisms have been proposed. NK cells act early on during the inductive phase of 
the immune response, suggesting that NK cells limit APC activity (Cook et al., 2013). However, 
other investigators have provided evidence that NK cells act directly on effector CD8+ T cells or 
on CD4+ T cells to restrict CD8+ T cell responses (Schuster et al., 2016; Kahan et al., 2014; 
Waggoner et al., 2012; Lang et al., 2013; Cook et al. 2015). IFN-I has also been shown to 
prevent CD8 T cell exhaustion during chronic infection if administered early on in infection 
(Wang et al., 2012). Other data show that IFN-I directly increases T cell numbers compared to 
IFNaR-/- T cells. There is evidence that IFN-I signaling into CD8+ T cells protects T cells from 
the regulatory effects of NK cells, implying that NK cells directly kill T cells (Crouse et al., 2014; 
Xu et al., 2014). This and other data have supported the notion that type-1 interferon promotes 
primary T cell responses during chronic infection by protecting CD8+ T cells from direct killing 
by NK cells. Similar to IFN-I, IFNg also promotes T cell responses by acting directly on T cells. 
Thus, IFNgR+ T cells accumulate more than IFNgR- cells. However, the role of IFNg signaling 
in protecting T cells from direct NK cell killing has not been reported.  
Here we examined whether IFNg signaling protects T cells from NK cell inhibition and 
we examined whether NK cells limit APC frequency or activity to restrict T cell responses by 
comparing T cell and APC activity in NK-replete or NK-depleted mice (Figure 1). We found that 
IFNg signaling into T cells does not protect them from direct NK cell killing, suggesting that NK 
cells do not act directly to regulate T cell function. However, we found that NK cell depletion 
increases processing of a fluorescent model antigen, DQ-OVA, in some APC populations, most 
notably that of monocytes. Based on these studies examining IFNg and DQ-OVA, NK cells act 














Mice C57BL/6 mice were purchased from Jackson ImmunoResearch Laboratories. P14 TCR-
transgenic mice specific for the LCMV epitope GP33 were crossed to C57BL/6.Ly5a+ or 
C57BL/6.IFNgR-/- mice to generate TCR-transgenic Ly5a+/+ and IFNgR-/- mice. SMARTA 
TCR-transgenic mice specific for the LCMV epitope GP61-80 were crossed to C57BL/6.Ly5a+/+ 
or C57BL/6.IFNgR-/- mice to generate TCR-transgenic Ly5a+/+ and IFNgR-/- mice. 
C57BL/6.Ly5a-/- mice were crossed with C57BL/6.Ly5a+/+ mice to generate C57BL/6.Ly5a+/- 
F1 heterozygotes. All mouse experiments were approved by the University of North Carolina at 
Chapel Hill Institutional Animal Care and Use Committee, and all mice were house in DLAM 
facilities in the Upper Basement of the Genetic Medicine Building on the University of North 
Carolina at Chapel Hill Medical School’s campus. 
 
Splenocyte Cell Purification Isolated spleens were homogenized, spun down, and lysed with 
0.83% NH4Cl ACK Lysing Buffer (Lonza), and quenched with 1% RPMI (Lonza) media. The 
cells were then washed twice with 1% RPMI (Lonza) media, counted, and re-suspended at a 
final concentration of 8 x 106 cells/mL in 10% RPMI (Lonza) media. A volume of 200 uL of each 
sample was added to a 96 well plate and surface stained. 
 
Adoptive Transfer Two types of experiments were carried out in this study, utilizing either 
P14/Ly5a and P14/IFNgR-/-  or SMARTA/Ly5a and SMARTA/IFNgR-/-  mice. The spleens of 
each donor mouse were purified as above, and a concentration of 2 x 106 cells/500 uL of each 
of these spleens were transferred via an intravenous (i.v) injection into naïve B6.Ly5a+/- host 
mice, or 2 x 104 cells/500 uL into mice to be infected at a later time point. 
 
Mouse NK Cell Depletion and Infection Mice utilized in this study were B6.Ly5a+/- 
heterozygotes that had undergone the adoptive transfer described above. They were depleted 
of NK cells on days 3 and 2 prior to infection with the antibody NK1.1 (BioXCell) or isotype 
control (BioXCell) via an intraperitoneal (i.p.) injection. The mice were then infected with the 
Clone 13 strain of Lymphocytic Choriomeningitis Virus (LCMV) at a concentration of 2 x 106 
PFU/500 L via an intravenous (i.v.) injection, or they were infected with the Armstrong strain at a 
concentration of 2 x 106 PFU/500 uL via intraperitoneal (i.p) injection. Spleens were harvested 
at day 2, 3, or 8 post infection and isolated cells were analyzed as described below. 
 
Intra-Cellular Cytokine and Surface Staining (ICCS) Purified spleen cells were incubated for 
5 hours at 37℃ with 1x BFA and either GP33, or NP396 peptides to stimulate immune-dominant 
virus-specific CD8+ T cells or with GP61-80 peptide to stimulate virus-specific  CD4+ T cells. 
The cells were then stained for surface markers such as CD4 (BioLegend), CD8 (BioLegend), 
CD44 (BioLegend), Ly5a (BioLegend), and Ly5b (BioLegend) at a concentration of 1:300 in 
FACS Buffer (DPBS (Lonza), 10mg/mL BSA (Sigma), 0.12% Sodium Azide (Sigma)), fixed and 
permeabilized, and then stained for intracellular cytokines with antibodies against TNF 
(BioLegend) and IFNg (eBioscience) . The cells were then run on FACS Calibur flow cytometer 
(Cytek) and analyzed using FlowJo software (TreeStar). Other non-stimulated spleen cells were 
then co-stained with antibodies against CD8 (BioLegend), CD4 (BioLegend), CD44 
(BioLegend), NK1.1 (BioLegend), Thy1.1 (BioLegend), IFNg-R (BD Biosciences), Ly5a 
(BioLegend), and Ly5b (BioLegend) at a concentration of 1:300 in FACS Buffer and analyzed 
using flow cytometry. 
 
DQ-OVA Incubation A volume of 100mL of purified splenocytes at a concentration of 8 x 106 
cells/mL was added to a 96 well flat bottom plate in the presence or absence of 50mL of varying 
concentrations (1:50-1:400) of DQ-OVA (Molecular Probes). Media was then added to each well 
to bring the final well volume up to 200mL and the plates were covered and placed at either 4 
oC or 37 oC for 80 minutes. The cells were then transferred to a 96 well U-bottom plate, washed 
twice with FACS buffer (DPBS (Lonza), 10mg/mL BSA (Sigma), 0.12% Sodium Azide (Sigma)), 
and surface stained for CD11b (BioLegend), CD11c (BioLegend), and MHC-II (BioLegend). The 
samples were analyzed using four-color flow cytometry with a BD Biosciences FACS-Calibur 





















NK cell depletion results in an increased T cell response. Previous studies have indicated 
that NK cells act in some manner to inhibit T cell responses during chronic infection (Cook et al., 
2012; Cook et al., 2015). We observed the relative abundance of both CD4+ and CD8+ T cells 
was examined in mice treated with isotype treatment or depleted NK cells during both chronic 
(Cl13) and acute (Arm) infections. CD8+ T cell frequencies were increased upon infection by 
LCMV, with an even larger T cell expansion observed upon NK cell depletion (Figure 2A). 
Conversely, CD4+ T cells did not have a significant increase in cell frequencies upon NK cell 
depletion. NK cell numbers naturally decrease over the course of infection, and NK cell 
depletion through the use of the antibody NK1.1 was confirmed through the use of flow analysis 
technology (Figure 2B). Consistent with our earlier findings we found that NK cell depletion 
improved overall T cell response in chronic, but not acute infection (Figure 2C). The beneficial 
effects of NK cell depletion were only significant in CD8+ T cells, but an observable increase in 
CD4+ T cells was still seen (Figure 2C). This is similar to previous data, supporting the 
conclusion that NK cells act in some manner to regulate the abundance of T cells during chronic 
infection (Paolini et al., 2015). 
 
Direct IFNg signaling into T cells does not protect T cells from NK cell regulation. It has 
been shown that IFN-I signaling protects T cells from NK cell regulation, suggesting a direct 
mode of action of NK cells on T cell expansion (Crouse et al., 2014; Xu et al., 2014). Our lab 
has shown that IFNg increases T cell numbers in mice, acting directly through IFNgR on T cells. 
We considered that IFNg signaling into T cells may protect them from being killed by NK cells. 
Previous studies have shown that IFNgR-/- mice have increased viral loads due to 
limited T cell expansion compared to WT individuals. In order to minimize the confounding 
effects of varied viral titers between KO and WT individuals, we performed an adoptive transfer 
experiment by co-transferring WT and IFNgR-/- T cells into the same recipient mice. These 
hosts were then infected and we analyzed the donor T cell responses (Figure 3A). This allowed 
us to observe donor cell responses in the same host environment and thus control for 
differences in viral loads between the two genotypes (Whitmire et al., 2005). The KO of the 
IFNgR was confirmed in IFNgR-/- mice through the use of flow analysis technology, as 
IFNgR+/+ cells stained positive with the use of anti-IFNgR whereas IFNgR-/- stained negative 
(Figure 3B). To facilitate these studies we used P14 TCR transgenic mice, whose CD8+ T cells 
are specific for the GP33-41 epitope of LCMV. 
Following infection, differences in genetic markers (WT cells were Ly5a+ and KO cells 
were Ly5a-) allowed us to observe and quantify the donor cell populations individually in hosts 
(Ly5a+/-) that had been depleted of their NK cells and subsequently infected with either acute 
(Armstrong) or chronic strains (Clone 13) of the LCMV virus (Figure 3C).  There was a trend 
toward an increase in the number of WT P14+CD8+ T cells over IFNgR-/- P14+CD8+ T cells in 
the same acutely infected mice. However, this ratio of WT to IFNgR-/- cells was similar when 
NK cells were depleted (Figure 3D, left). This may be due to WT cells’ increased ability to 
engraft or proliferate in the host environment, or it may be due to some mechanism of action 
that reduces IFNgR-/- cells from surviving in the host environment. The difference in WT over 
IFNgR-/- cells was further increased during chronic infection, with no real change in ratio of WT 
to IFNgR-/- cells upon NK cell depletion (Figure 3D, right). 
We also found support for previous data suggesting that the overall T cell response is 
improved upon NK cell depletion. Both WT and IFNgR-/- transfer cells had significantly 
increased responses in NK depleted mice compared to isotype treated only in chronically 
infected mice compared to acute infection (Figure 3C). However, the ratio between WT and 
IFNgR-/- cells did not have a significant change in response to NK cell depletion, suggesting 
that IFNg signaling is insufficient to protect T cells from NK cell regulation (Figure 3C). 
Previous data showed that NK cell depletion improves virus specific CD4+ T cell 
responses after LCMV infection (Cook et al., 2012). After looking at the effects of NK depletion 
on the ratio between WT and IFNgR-/- CD8+ T cells, we decided to look at the same effect on 
transferred CD4+ T cells. To do this we utilized SMARTA transgenic mice, which have a T cell 
receptor that is specific to the GP61-80 epitope of the LCMV virus (Figure 4A). This allowed us to 
track these specific cells’ response to infection by LCMV. Similar to our data utilizing P14+CD8+ 
mice we found an improved expansion of WT over IFNgR-/- T cells in both isotype and NK cell 
depleted mice after acute infection (Figure 4B). However, this ratio did not change upon NK cell 
depletion as suggested in P14+CD8+ studies of acute infection (Figure 4C). The same results 
were seen upon chronic infection, as the ratio of WT to IFNgR-/- T cells was not improved upon 
NK cell depletion.  
As seen previously, there was no increase in overall T cell responses as a result of NK 
cell depletion during acute infection (Figure 4C). However, there was an increase in the overall 
CD4+ T cell response with NK cell depletion (Figure 4D). This increase in T cell response was 
less pronounced than that seen for CD8+ T cells, and only significant during chronic but not 
acute infection. These findings suggest that IFNg does not protect T cells from the regulatory 
effects of NK cells. 
 
Optimization of a protocol for the use of DQ-OVA to quantify antigen processing 
by APCs. Previous data has shown that T cell accumulation is improved when NK cell depletion 
occurs in the first few days of infection. Since APCs present antigen to induce T cells as an 
early response of the immune system, it may be that NK cells affect the T cell response either 
by eliminating APCs, or inhibiting APCs’ ability to process and present antigen. To test this 
hypothesis, we utilized the antigen DQ-OVA to track the antigen presenting ability of APCs in 
response to the depletion of NK cells during chronic infection. 
DQ-OVA is a self-quenched, non-fluorescing compound that exhibits a green 
fluorescence in the interior of the cell when endocytosed and cleaved by enzymes contained 
within APCs (DQ-Ovalbumin, 2001). DQ-OVA acts as a surrogate antigen, giving us the ability 
to observe the efficiency of uptake and processing of antigen by APCs. It can also be used to 
assess T cell stimulation by APCs. Utilizing this compound allowed us to directly see the effect 
that depletion of NK cells has on APC function. However, it was necessary to produce and 
optimize a protocol for the in vitro use of DQ-OVA for the evaluation of APC antigen processing 
ability in the presence or absence of NK cells.  
As mentioned above, we sought to consider whether NK cells affect APC numbers and 
activity. In order to do this, we needed to establish an antigen presentation assay. The goal of 
this assay was to  expose APCs to antigen and assess their ability process the foreign particles. 
We then went on to compare APC function in NK cell-replete and NK cell-depleted mice. DQ-
OVA has been used as a reagent and subsequently analyzed using flow cytometry by several 
groups (Luque et al., 2013; Young et al., 2007; Bimczok et al., 2010; Olivar et al., 2013; Nayak 
et al., 2006; Wahid et al., 2005). However, different labs utilized diverse protocols with varying 
incubation times and DQ-OVA concentrations. 
To optimize the assay for our model system. Cells were incubated at either 4 oC to 
provide a negative control due to limited antigen uptake by APCs at low temperatures, or at 37 
oC for optimal cell processes to occur. The main variable that was altered was the concentration 
of the reagent; we utilized concentrations from 1:4 to 1:1600 and surface stained to track 
various APC populations (Figure 5A).  After utilizing different concentrations of reagent, a dose 
response was developed which showed an increase in fluorescence as the concentration of 
DQ-OVA increased (Figure 5B). Samples were incubated with DQ-OVA at 4 oC, as endocytosis 
of antigen by APCs is slow and incubation would theoretically give a result equivalent to a 
negative sample where no reagent was added. Based on these findings an optimal 
concentration to total volume of 1:200 to 1:400 DQ-OVA was chosen. Concentrations higher 
than this resulted in non-specific binding of the reagent to non-APC cells, and concentrations 
lower than 1:200 resulted in dim fluorescence of target cell populations. These results show that 
the addition of DQ-OVA results in a measurable fluorescence as a result of the reagent. 
We next examined the ability of specific subsets of APCs, such as dendritic cells (cDCs), 
macrophages, and monocytes to take up and present antigen under different concentrations of 
DQ-OVA. APC populations are identified using the marker MHCII+, whereas cDC populations 
are defined by CD11c+/MHCII+ and macrophages by CD11b+/MHCII+. The mean fluorescence 
of each cell was analyzed and used to show that this increased fluorescence was due to 
increased antigen presentation function by individual APCs rather than an increased number of 
cells (Figure 5C). This implies that there is less competition among cells in the presence of 
higher concentrations of reagent. However, we observed non-specific binding at high DQ-OVA 
concentrations (data not shown). We thus decided on an optimal ratio of DQ-OVA to cells as 1 
to 200 for our model system. 
 
NK cell depletion improves antigen processing by monocyte populations. Once we 
optimized an assay to observe the antigen presenting abilities of APCs, we sought to determine 
if the depletion of NK cells affected the ability of APCs to process and present DQ-OVA during 
infection. Viral infection can either activate APCs to uptake various antigens, or it can shut down 
endocytosis processes in order to present just one type of antigen to cytotoxic T cells. In order 
to make sure that our assay parameters were not affected by infection we examined how 
CD11c and CD11b subsets responded to a viral challenge by LCMV. We found that there was 
no trend towards increased DQ-OVA uptake and processing between APCs from naïve and 
infected mice (Figure 6). This was true for both DC subsets (Figure 6A) and macrophage 
subsets (Figure 6B). Thus, infection does not affect the ability of primary DCs and macrophages 
to take up DQ-OVA in our model assay. 
It has been shown that the depletion of NK cells increases the ability of T cells to 
proliferate and clear LCMV infection (Cook, et. al, 2012). This suggests that NK cells mediate T 
cell responses, either by inhibiting T cells directly or acting on a T cell activator. Since this T cell 
activating response is seen primarily in the first few days of infection, we hypothesize that NK 
cells play a role in APC function, either by eliminating APCs or inhibiting their ability to take-up 
and present T cell activating antigen. We explored this by determining how APC uptake and 
presentation of DQ-OVA changed in response to NK cell depletion during LCMV infection 
(Figure 7). While there was no significant difference between infected primary DCs or 
macrophages (MHC II+/CDllc+ or MHC II+/CD11b+) with or without NK cells, we did see a 
significant increase in fluorescence for monocytic populations (MHC II-/CD11c+ or MHC II-
/CD11b+) that were isolated from infected, NK cell-depleted mice compared to NK-replete mice 
















The overarching goal of our research was to understand how NK cells regulate T cell 
responses. Such information will help us to understand how the immune system responds to 
chronic infections in humans, such as HIV and HCV, where T cells and NK cells are engaged. It 
will also aid in our treatment of many immunological deficiencies such as NK cell deficiency. 
The first part of our study examined whether IFNg was sufficient to protect T cells from direct 
killing by NK cells. Our results suggest that NK cell depletion improves the overall T cell 
response in mice infected with chronic LCMV (Cl13). We considered that IFNgR-/- T cells would 
be susceptible to NK cell inhibition since they tend to expand poorly compared to WT T cells. 
However, there was no preferential increases in IFNgR-/- T cells when NK cells were depleted. 
Thus, the ratio of WT to KO cells was not significantly altered by NK cell depletion. Similar 
findings were seen for CD8+ or CD4+ T cells regardless of the type of infection. These results 
led us to conclude that IFNg signaling is not sufficient to protect T cells from the regulatory 
effects of NK cells during infection. We also examined the impact of NK cells on APCs, which 
are essential cells involved in the stimulation of T cells. We observed that monocytic cells 
showed improved antigen processing ability when NK cells were removed, suggesting that NK 
cell depletion improves APC signaling to CD8+ T cells. 
 Others have shown that IFN-I is sufficient to protect T cells from NK cell regulation, 
suggesting a direct mechanism of action of NK cells on T cells (Crouse et al., 2014; Xu et al., 
2014). This discrepancy in conclusions may be explained by different modes of action by 
various cytokines. Whereas IFN-I signals T cells through the use of STAT1/2 and STAT4, IFNg 
primarily signals through the STAT1 pathway. These signaling pathways may differ in terms of 
the surface receptors that are induced following IFN-I signaling, affecting how NK cells interact 
with T cells. It is also worth noting the possibility that NK cells may act differently in vivo as 
compared to in vitro assays. This leaves open the possibility of an indirect mode of action of NK 
cell regulation, which is supported by the observation that the beneficial effects of NK cell 
depletion on T cell responses only occurs during the inductive phase of infection (Cook et al., 
2013). One explanation would be NK cell regulation of antigen presenting cell (APC) signaling to 
T cells, which may explain the decreased response of T cells in the presence of NK cells. Thus, 
the second part of our study examined APC presentation of antigen. We found evidence that 
APCs from NK cell-depleted mice were improved in their ability to process antigen, an effect 
that may explain how NK cell depletion improved T cell responses. Thus, NK cells appear to 
regulate antigen presenting cells to restrict T cell responses. 
Upon infection, APCs can become activated, increasing the amount of antigen they take 
up and process. However, we found that there is no clear evidence that infection increases DQ-
OVA uptake and processing. In other models DCs and macrophages shut down their antigen 
sampling processes when antigen is endocytosed, migrating to T cell areas to prime T cell 
responses (Young et al., 2007). This allows APCs to focus their efforts on stimulating one type 
of T cell rather than many different types. Thus, upon infection with LCMV, some APC 
populations may be limited in their ability to take up DQ-OVA—this results in an equal, or lesser, 
processing ability of DQ-OVA in infected APCs as compared to naïve APCs. However, 
monocytes did show a significant increase in DQ-OVA uptake upon infection. One explanation 
for this is that an immature subset, monocytes, continue to sample molecules in the extracellular 
fluid, and upon endocytosis and processing of antigen they mature into APC populations that 
are unable to perform endocytosis. Perhaps monocyte populations are stimulated to take up 
more DQ-OVA when exposed to LCMV. We also found an increase in DQ-OVA processing of 
DC and macrophage populations in response to NK cell depletion. This positive correlation was 
most apparent in monocyte populations (MHC II-/CD11c+ or MHC II-/CD11b+). While we are 
not sure why this positive increase in DQ-OVA processing occurred in these populations upon 
the depletion of NK cells--however, this result suggests that future studies should focus on 
monocyte populations and whether or not they contribute to antiviral T cell responses. Since the 
sample size is small (n=2) and the pattern is not observed in other populations, it is necessary 
to repeat this study in order to draw a conclusion for this population. Although there appears to 
be a slight increase in fluorescence with NK cell depletion, it was observed that background 
fluorescence of samples without added DQ-OVA also saw an increase in brightness in the FITC 
channel. Thus, this positive shift may be due to a reaction to the NK1.1 antibody rather than a 
true shift due to lack of NK cells. This experiment will need to be repeated with the addition of 
uninfected NK cell depleted controls to determine if the observed pattern is repeated. 
We revealed a potential link between NK cells and antigen presentation by APCs 
through the application of DQ-OVA as an antigen surrogate. One caveat with this reagent is that 
we cannot discern between antigens that have been processed and presented on the surface of 
the cell versus antigens that have been processed but remain inside the cell. Thus, using DQ-
OVA without subsequent T cell stimulating assays is only useful in determining whether NK cells 
affect APC uptake and processing of antigens, but not necessarily antigen presentation. Future 
application of this study will involve analyzing T cell stimulation following DQ-OVA stimulation. 
Overall we examined whether IFNg protects T cells from direct killing by NK cells, and 
whether NK cells limit APC activity to reduce T cell responses (Figure 1). We determined that 
IFNg is not sufficient to protect T cells from the regulatory effects of NK cells, suggesting that 
NK cells do not act directly to curb T cell responses. However, we did find preliminary evidence 
that various APC populations are inhibited by NK cells. Future studies will aim to look more 
deeply at monocyte populations and the ability of antigen presenting populations to stimulate T 
cells with or without NK cells. Additionally, work is being done to observe the effects of NK cell 
depletion on myeloid-derived suppressor cell (MDSCs) populations. MDSCs have been shown 
to regulate both NK cells and T cells in the tumor environment, but have not been extensively 
researched in relation to chronic viral infection(Sato et al., 2015; Goh et al., 2013; Ostrand-
Rosenberg et al., 2018; Noris et al., 2013). Another possible mode of action is that NK cells 
affect the structure and function of fibroblastic reticular endothelial cells, which have been 
shown to both enhance and inhibit T cell expansion in the spleen and lymph nodes (Siegert et 
al., 2011; Fletcher et al., 2013). Further research will be necessary to determine how NK cells 



























Figure 1. Two hypotheses for how NK cells regulate T cell accumulation. A) Direct IFNg 
signaling into T cells improves their accumulation. This may be achieved by preventing NK cell 
recognition and killing of T cells. B) T cells require APCs to proliferate. NK cells may inhibit APC 




Figure 2. T cell responses in mice depleted of Natural Killer Cells. NK cell-replete or NK 
cell-deplete mice were injected with LCMV-Arm or LCMV-Cl13. T cell responses at day 8 were 
determined by flow cytometry. A) Spleen cells surface were stained with antibodies to CD8, 
CD4, and CD44. The FACS dot plots show representative gating patterns, with numbers 
representing the percentage of activated T cells in the oval gates. B) The histograms show the 
percentage of NK cells in the spleen. C) The total number of activated CD8 and CD4 T cells per 
spleen in mice containing or not containing NK cells. The improvement in T cell response due to 
NK cell depletion is more pronounced in chronic than acute infection. Statistics were performed 
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Figure 3. Direct IFNg signaling does not protect CD8+ T cells from NK cell inhibition. A) 
Timeline of experiments using P14 donor mice. Equal numbers of P14/IFNγR-/- donor T cells 
were co-transferred to B6.Ly5a+/- mice on day -5 before infection. On days -2 and -3 half of the 
host mice were treated with NK1.1 to deplete their NK cells, and the rest were left undepleted. 
On day 0, six of the eight mice in each experiment were infected with either an LCMV-Arm or a 
LCMV-Cl13. Spleens were harvested on day 8 and analyzed. B) Before the dual transfer 
P14/IFNγR-/- donor mice spleens were stained to insure that the IFNγ receptor had been 
effectively knocked out. C) Representative gating for the analysis of donor populations in the 
host mice. After the harvest on day 8, spleen cells were surface stained. CD8+/CD44+ cells 
were gated off of the total live cells. The WT donors were then visible as Ly5a+/Ly5b- and the 
IFNγR-/- donor cells as Ly5b+/Ly5a-, whereas the host cells are Ly5a+/Ly5b+. D) The number 
of each donor T cell population per spleen. The symbols connected by lines represent T cells in 









Figure 4. Experimental Design to assess whether IFNg protects CD4+ T cells from NK cell 
inhibition. A) Timeline of experiments using SMARTA donor cells. SMARTA/Ly5a and 
SMARTA/IFNγR-/- donor cells were co-transfered to a B6.Ly5a+/- host on day -5 before 
infection. On days -2 and -3 the rest were treated with NK1.1 to deplete their NK cells. On day 
0, six of the eight mice in each experiment were infected with either LCMV-Arm or LCMV-Cl13 
Spleens were harvested on day 8 and analyzed. B) Representative gating for the analysis of 
donor populations in the host mice. After the harvest on day 8, spleen cells were surface 
stained. CD8+/CD44+ cells were gated off of the total live cells. The WT donors were then 
visible as Ly5a+/Ly5b- and the IFNγR-/- donor cells as Ly5b+/Ly5a-, whereas the host cells are 






















































































































plots show cells from a mouse given LCMV-Arm. The number of each donor population per 
spleen is shown in the graph, compared using a paired t-test with a sample size of n=3 for each 
group. D) The effects of infection on donor cell expansion in Clone 13 infected mice. 
Populations were seen to expand upon infection, with the population of WT cells expanding 
more proficiently than the KO cells. The percentage of each donor population was then 
compared between the isotype and NK cell depleted mice using a paired t-test with a sample 










Figure 5. Optimization of DQ-OVA to assess APC uptake and processing of antigen. In an 
effort to optimize DQ-OVA for flow cytometry, cells were exposed to different concentrations of 
DQ-OVA. Naïve splenocytes were exposed for 80 minutes at either 4 oC or 37 oC and then 
surface stained for. Markers of distinct APC subsets. A) An example of gating strategy for DQ-
OVA presentation. Samples were first gated on all live cells. Autofluorescence and nonspecific 
binding was then gated out of the sample. Various subsets of splenocytes including non APCs 
(MHC II-/CDllc-), monocytes (MHC II-/ CD11c+) (data not shown), all MHC II+ cells, and DCs 
(MHC II+/CD11c+) could be identified. MFI of each subpopulation was then graphed and mean 
MFI determined. This gating strategy was used for all experimental samples, including CDllb+ 
samples. B) Geometric mean of MHC II+ and dendritic cell populations. An increase in 
concentration of reagent resulted in an increase in MFI due to an increase in the number of cells 
that process and fluoresce DQ-OVA. C) The relative percentages of cells that are positive for 
DQ-OVA presentation at varying concentrations. As the concentration of antigen increases, the 
number of cells processing and fluorescing with DQ-OVA also increases. 
 
Figure 6. Ability of various splenocyte populations to process DQ-OVA in the presence of 
virus. B6 mice were either infected with 2 x 106 PFU/500mL of LCMV or left uninfected, and 
spleens were harvested at day 2 post-infection. Cells were incubated with a DQ-OVA 
concentration of 1:400. The mean fluorescence of DQ-OVA was calculated, and naïve cells 
from each population are compared against their equivalent infected populations. Sample size is 
n=1 for naïve and infected groups from one experiment. Similar trends were observed in other 
experiments (data not shown). A) Depicts cells stained with CD11c and MHC II. Groups whose 
data is shown are DCs (MHC II+/CD11c+), Monocytes (MHC II-/CD11c+), non-APC cells (MHC 
II-/CD11c-), and MHC II+. B) Depicts cells stained with CD11b and MHC II. Groups whose data 
is shown are macrophages (MHC II+/CD11b+), Monocytes (MHC II-/CD11b+), non-APC cells 
(MHC II-/CD11b-), and MHC II+. 
 
Figure 7. The impact of NK cell depletion on the bility of various splenocyte populations 
to take up and process DQ-OVA. B6 mice were infected with 4 x 106 PFU of LCMV and 
spleens were harvested at day 3 post-infection. The cells were incubated with a DQ-OVA 
concentration of 1:200. The mean fluorescence of DQ-OVA was calculated, and naïve cells 
from each population are compared against their equivalent isotype and NK depleted 
populations. Sample size is n=2 for naïve, isotype, and NK1.1 groups, which were compared 
using an ANOVA statistical analysis. Similar trends have been observed in other experiments 
(data not shown). A) Depicts cells stained with CD11c and MHC II. Groups whose data is 
shown are DCs (MHC II+/CD11c+), Monocytes (MHC II-/CD11c+), non-APC cells (MHC II-
/CD11c-), and MHC II+. B) Depicts cells stained with CD11b and MHC II. Groups whose data is 
shown are macrophages (MHC II+/CD11b+), Monocytes (MHC II-/CD11b+), non-APC cells 
(MHC II-/CD11b-), and MHC II+. 
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